Sofinnova Partners Raises €82M to Back Medtech Startups

Sofinnova Partners has reeled in €82 million to invest in medical technology companies over the next five years, as first reported by Fierce Biotech.

The figure anchors the Paris-based venture capital firm's newest fundraising effort. The €82 million pool will be directed at medtechs — companies developing medical devices, diagnostics and related health technologies — across a five-year investment horizon, according to the report.

The raise extends Sofinnova's long-standing position in European life-sciences investing. The firm has spent decades backing healthcare and technology startups, and the new capital keeps medical technology firmly within its mandate at a time when the sector continues to attract dedicated funding streams from specialist investors.

The €82 million commitment signals where Sofinnova sees deployable opportunity. By targeting medtechs specifically, the firm is allocating capital to a segment of healthcare innovation that sits apart from biopharmaceutical drug development, which has absorbed the bulk of venture money in the life sciences in recent years.

The five-year window matters. It frames how quickly the firm intends to put the money to work and gives portfolio companies a sense of the fund's deployment rhythm. A defined investment period of that length is standard practice among European venture funds, which typically spread commitments across a series of initial and follow-on investments rather than deploying capital in a single burst.

Fierce Biotech's report did not disclose the fund's limited partners, the names of any intended portfolio companies, or whether the €82 million represents a final or interim close. Those details, when they surface, will clarify the scale of the fundraising relative to Sofinnova's earlier vehicles.

What the number does establish is intent. An €82 million pool dedicated to medtech over five years implies a strategy of backing a concentrated set of companies, with individual checks sized to stretch the capital across the full investment period. For medical technology founders in Europe and beyond, the fund represents a new source of specialist financing from a firm with a decades-long record in healthcare investing.

The raise lands amid a selective funding environment for medtech. Venture dollars across the broader life-sciences sector have tightened since the highs of 2021, and investors have concentrated on later-stage assets with clearer paths to commercialization. Against that backdrop, a dedicated medtech vehicle of this size gives Sofinnova capacity to move when opportunities meet its criteria.

Sofinnova's decision to time-box the deployment over five years also sets expectations for returns. Venture funds typically operate on a ten-year lifecycle, with the initial five years reserved for new investments and the second half for managing and exiting positions. The structure suggests Sofinnova plans a steady cadence of medtech deals through the end of the decade.

For the medical technology ecosystem, the practical effect is straightforward: €82 million of fresh, purpose-directed venture capital will reach medtech companies between now and the end of the five-year window, with Sofinnova Partners acting as the gatekeeper deciding which startups receive it.